L

Lillestol Research LLC | Fargo, ND

Research site
(Unclaimed)
Location
4450 31ST Avenue South Suite 101, Fargo, North Dakota, United States of America
Site insights

Top conditions

Diabetes Mellitus (11 trials)

Type 2 Diabetes Mellitus (10 trials)

Cardiovascular Diseases (5 trials)

Atherosclerosis (3 trials)

Type 1 Diabetes Mellitus (2 trials)

Top treatments

LY3298176
Tirzepatide
Semaglutide
PF-06882961
ARO-APOC3
Lasmiditan
AD109
Rimegepant
Drospirenone
LY3209590

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

16 of 35
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes (SOUL)

The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease. Participants...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Placebo (semaglutide)

a Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat (an aldosterone synthase inhibitor), administered on a background of a...

Enrolling
Hypertension
Drug: lorundrostat Dose 2
Drug: lorundrostat Dose 1

This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 dia...

Enrolling
Obesity
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Insuline glargine U100 (reduced)

This is a safety study to evaluate BOS-580 administered subcutaneously over 12 weeks in Part A or 24 weeks in Part B.

Enrolling
Nonalcoholic Steatohepatitis (NASH)
Drug: BOS-580
Drug: Placebo

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks an...

Enrolling
Migraine
Drug: Placebo
Drug: Lasmiditan

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide

This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weig...

Active, not recruiting
Overweight
Obesity
Drug: Tirzepatide
Drug: Placebo

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Enrolling
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Obicetrapib

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting
Coronary Heart Disease (CHD)
Drug: Evolocumab
Drug: Placebo

The primary objective of this study is to evaluate the impact of LF111 and drospirenone (DRSP) 3.5 mg chewable tablets on bone mineral density (BMD)...

Enrolling
Change in Bone Mineral Density
Bone Loss
Drug: LF111 (drospirenone 4 mg oral tablet) or drospirenone (DRSP) 3.5 mg chewable tablet

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Olpasiran

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Ob...

Enrolling
OSA
Drug: Placebo
Drug: AD109

This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular...

Enrolling
Cardiovascular Disease
Drug: Semaglutide
Drug: Cagrilintide

This is an open-label extension of the parent studies AROAPOC3-2001 and AROAPOC3-2002. Adult participants with dyslipidemia who completed the blinded...

Active, not recruiting
Dyslipidemias
Drug: ARO-APOC3

The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the effi...

Enrolling
Hyperuricemia
Tophi
Drug: Tigulixostat
Drug: Placebo

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling
Chronic Kidney Disease
Inflammation
Drug: Ziltivekimab C
Drug: Placebo (Ziltivekimab B)

Trial sponsors

Lilly logo

Lilly (8 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems